Abstract: The present invention relates generally to the use of circulating cytochrome c as a biomarker of reperfusion injury that results from whole body ischemia. Circulating levels of cytochrome c can be used as predictor of survival rates and to assess the effects of interventions aimed at ameliorating mitochondrial injury during reperfusion. Whole body ischemia may be the result of cardiac arrest or from other hemodynamic crises, such as hemorrhagic shock.

Abstract: A device for sampling fluid from an earth formation is disclosed. The device includes: an inlet port disposable in fluid communication with the fluid in a borehole; an injector including an injection chamber in fluid communication with the inlet port, the injector configured to receive a portion of the fluid and direct the fluid toward an analysis unit for analyzing constituent materials in the fluid; and a high pressure valve configured to admit the portion of the fluid at a borehole pressure and release the portion of the fluid into the injector, the portion having a volume that is less than or equal to about one microliter. A system and method for analyzing constituents of fluid in a borehole in an earth formation is also disclosed.

Abstract: Biomarkers relating to glucose disposal rate, insulin resistance, and/or insulin resistance-related disorders are provided. Methods based on the same biomarkers are also provided.

Abstract: A method for assessing arteriosclerosis comprising measuring the serotonin level in whole blood, serum or platelet-rich plasma and rating the serotonin level on such a scale that the lower it is, the more serious the arteriosclerosis is.

Abstract: The present invention is directed, among other things, to using secondary metabolites in the mevalonate pathway (such as, for example, HMG) and/or structurally related compounds to mediate biological activities (e.g., for therapeutic applications) and/or as diagnostic agents. In some embodiments, the biological activities comprise one or more pleiotropic effects of statins (such as, for example, angiogenesis, promoting vascular function, anti-inflammatory action, immunomodulation, etc.). Also provided are methods of screening for mevalonate pathway secondary metabolites, methods of producing HMG, and methods of diagnosing comprising measuring amount of mevalonate pathway secondary metabolites.

Abstract: The invention relates to a method for diagnosing acute renal failure, comprising the step of determining a presence or absence or amplitude of at least three polypeptide markers in a sample, wherein the polypeptide marker is among the markers characterized in table 1 by values for the molecular weights and the migration time.

Abstract: Non-invasive methods of predicting embryo outcome by analyzing disclosed markers in embryo culture media.

Abstract: The present invention relates to the use of fish skin as novel industrial source of collagen. Advantageously, said skin is obtained after the filleting or cutting of the fresh fish and frozen immediately after filleting/cutting, thus guaranteeing a very good quality of the base material, both from the bacteriological standpoint and from the standpoint of the native property of the protein.

Abstract: An injection device (10) includes a carrier inlet (40), a sample inlet (46), waste outlet (44) and a chamber outlet (64) attached to separation column (66). Valves (52, 54, 56) are used to control flow such that sample flows into chamber (22) and is carried into the chamber outlet (42).

Abstract: The disclosure provides a method for quantitatively determining risedronate in a urine sample by adding an internal standard to the urine sample, applying the urine sample to a polymeric water-wettable reverse-phased sorbent preconditioned with methanol, washing the sorbent with TEA in water and formic acid in methanol, eluting risedronate with a mixture of methanol and water containing EDTA under vacuum, evaporating the eluted solution and reconstituting with a mixture of methanol and NH4OH buffer and analyzing the sample with a LC-MS/MS system.

Abstract: The present invention provides methods of diagnosing and identifying subjects as having GERD comprising detecting E-cadherin fragments in a biological sample from the subject. The invention further provides methods for identifying subjects as having heartburn that is responsive to proton pump inhibitor therapy and subjects having an increased likelihood of a rapid relapse of GERD after reducing the dosage of PPIs or terminating PPI therapy. In addition, the present invention provides methods for monitoring the healing of erosive and nonerosive esophagitis of GERD without the need for esophagogastroduodenoscopy or esophagogastroduodenoscopy and biopsy, respectively.

Abstract: The invention relates to a method of diagnosing or monitoring bipolar disorders, in particular bipolar I and bipolar II disorders, such as manic psychosis.

Abstract: A method for the superficial-phase chromatography of a product comprises the steps which are performed continuously in the following order, namely: an operation consisting in pumping a supercritical fluid; and operation consisting of injecting at least one sample of product into at least one chromatography column, a detection operation, and a fraction collection operation. The method comprises at least a first diversion along between an analytical channel and a preparatory channel, which diversion is performed prior to the supercritical fluid pumping operation and the analytical and preparatory channels each including respective supercritical fluid pumping operations. The method is also characterized in that the collection operation is common to both the analytical and preparatory channels. An installation used to implement one such method is described.

Abstract: A pressure gauge mounted to a pump or a back pressure regulator in an HPLC, SFC, or SFE system provides improved solvent exchange and improved measurement precision. A through hole having an inside diameter of 1.0 mm is made in a hexagonal member similar in shape to a pipe joint. A part of the hexagonal member is cut away to form a flat surface such that the distance to the outside periphery of the through hole is 0.5 mm to serve as a strain-measurement strain gauge attaching surface. One strain gauge is attached to the center of the strain-measurement strain gauge attaching surface, and two strain gauges are attached for temperature correction, one on the same surface as the strain-measurement strain gauge attaching surface and the other on an outside surface of the hexagonal member.

Abstract: Disclosed are compounds of formula (I), a derivative, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer. Also disclosed are methods of preparing compound of formula (I), a derivative, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer. Further disclosed are methods of conducting drug discovery and research comprises applying the compound of formula (I), a derivative, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer in an investigation.

Abstract: The invention relates to a method of diagnosing or monitoring major depressive disorder.

Abstract: The invention relates to a method of diagnosing or monitoring multiple sclerosis.

Abstract: A physiologically active substance collecting device, includes: a collecting section brought into contact with a body surface of a living organism to acquire a physiologically active substance from the body surface; and a liquid sending means for sending a solvent to the collecting section, the collecting section having an aperture at which the solvent flown by being sent from the liquid sending means contacts the body surface.

Abstract: A method for performing an assay of at least one target vitamin in an oral care product includes: a) preparing a first analyte comprising a standard solution of the target vitamin to be assayed; b) preparing a second analyte comprising a sample solution derived from the oral care product containing the target vitamin; c) preparing a third analyte comprising a placebo solution derived from the oral care product which does not contain the target vitamin; d) chromatographically analyzing and providing a chromatogram for each said analyte; e) comparing the chromatograms of the first and second analytes to determine the amount of target vitamin in the sample solution; and f) comparing the chromatograms of the second and third analytes to verify that the assay is specific for the target vitamin.

Abstract: Method for analyzing one or more pesticidal compounds present in amounts of less than or equal to 0.00005 mg/kg of a sample, comprising the following steps: a) preparation of the sample; b) optional dilution of the sample prepared; c) direct analysis of the optionally diluted sample by high performance liquid chromatography (HPLC)/tandem mass spectrometry (MS/MS).

Abstract: A method for the diagnosis of tubular kidney diseases comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide marker being selected from the markers characterized in Table 1 by values for the molecular masses and migration times.

Abstract: The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I: or a prodrug or pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

Abstract: Chiral selectors having ?-unsubstituted ?-amino acid derivatives of the structure: a stationary phase for separating substance mixtures containing the chiral selector, and processes for separating mixtures of chiral substances, including enantiomers, and especially enantiomers of substances selected from ?-amino acids and derivatives thereof, ?-amino acids and ?-hydroxy acids are provided.

Abstract: A liquid chromatograph apparatus capable of eliminating a deviation of measurement results originating from an instrumental error is provided. According to the present invention, a mobile phase arrival time T of the liquid chromatograph apparatus is determined in advance. The mobile phase arrival time T is a time taken for a mobile phase mixed by a pump to reach a detector. When operating the liquid chromatograph apparatus, sample injection into the mobile phase is started after a time corresponding to the mobile phase arrival time T passes. Collection of data output from the detector is started after a predetermined time passes after starting the sample injection into the mobile phase.

Abstract: The process for the diagnosis, early detection and prognosis of the clinical development of autosomal-dominant polycystic kidney disease (ADPKD) comprises the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide markers being selected from the markers characterized in Table 1 by values for the molecular masses and migration times.

Abstract: Provided herein are methods of liquid column chromatography in which preparative chromatography is performed in-line with analytical chromatography. In particular aspects a monolithic preparative column is used to purify an analyte of interest from a mixture of other substances by applying the mixture to the column, reversing the flow through the column to elute the analyte, which is applied to an analytical column provided in-line with the preparative column. In other aspects, a single monolithic column is used to perform both the preparative chromatography and analytical chromatography steps in succession. In another aspect, a chromatography system is provided to perform preparative and analytical chromatography using a single monolithic column.

Abstract: The invention relates to the treatment and diagnosis of organ dysfunction caused by ischemia reperfusion injury. In particular, the invention relates to sphinganine-1-phosphate, a sphingolipid metabolite, and its use in the diagnosing, preventing, and/or treating ischemia reperfusion-associated disorders, including, without limitation, disorders of the kidney, liver, lung, brain, and heart.

Abstract: The use of neuromedin U receptor agonists to elevate the levels of GLP-1 and/or PYY in an individual in need of an increase in its levels of GLP-1 and/or PYY is described. Further described is the use of neuromedin U receptor agonists to lower the levels of glucagon in an individual in need of lowered glucagon levels. Thus, methods for elevating GLP-1 and/or PYY and lowering glucagon levels in an individual by administering to the individual compositions comprising a neuromedin U receptor agonist and optionally one or more dipeptidyl peptidase IV (DPP-IV) inhibitors are described.

Abstract: The invention provides methods and compositions for determining whether a subject is at risk of developing age-related macular degeneration, for example, the wet or neovascular form of age-related macular degeneration. The method involves determining whether the subject has a protective variant and/or a risk variant at a polymorphic site in the HTRA1 gene. In addition, the invention provides a method of treating or slowing the progression of age-related macular degeneration by reducing the expression of the HTRA1 gene, or reducing the biological activity of the HTRA1 gene product.

Abstract: Embodiments of the present invention are directed to resonating detection devices in which the sample flows through a conduit having a section in which the conduit is grouped or concentrated with the point of maximum movement.

Abstract: Devices and techniques for using four wave mixing in optical sensing of various materials, including isotopes, chemical and biological substances.

Abstract: Embodiments of the present invention are directed to kits and methods for the detection of toxins produced by cyanobacteria. The methods and kits feature sample preparation steps with weak cationic and anionic exchange resins and small particle analytical columns operating at 4,000 to 15,000 psi.

Abstract: The present invention provides methods useful for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, and diagnostic methods and kits thereof.

Abstract: The present invention features devices and methods of making such devices for performing liquid chromatography having at least one wetted surface having a composition of a polysilazane.

Abstract: The present invention relates to a new HPLC method for the analysis of the drug substance bosentan and related substances and to the use of said substances as reference standards and markers.

Abstract: MEX3C deficiency impairs the development of white and brown adipose tissue. Hence the present invention provides, among other things, a method of screening a candidate compound for activity in inhibiting fat deposition in a subject in need thereof and/or treating a condition in a subject in need thereof, comprising: (a) contacting a candidate compound to a cell that expresses MEX3C protein; and then (b) detecting a quantity of expression of the MEX3C protein in the cell; a depression in the expression of MEX3C protein when the candidate compound is contacted thereto as compared to that expressed when the candidate compound is not contacted thereto indicating the compound is active in inhibiting fat deposition and/or treating a condition in a subject in need thereof. Methods of treatment and screening subjects are also described.

Abstract: The invention provides novel fragments of proBNP and NTproBNP, particularly useful in prognosing or diagnosing acute heart failure, chronic heart failure or sepsis.

Abstract: A tight-spot fitting includes an elongated body configured to be inserted into and extracted from an aperture of a device, a user-operable head configured to be manipulated by a user to rotate the elongated body with respect to the aperture of the device, a depression in the user-operable head dimensioned and configured to receive a corresponding driver, and a through-bore extending through the elongated body and the user-operable head into the depression. The through-bore is configured and dimensioned to receive a line therethrough such that when the elongated body portion is inserted into the aperture, the line spans the aperture and through-bore, and extends through the depression.

Abstract: The present disclosure relates to methods for separating or isolating a peptide using reverse phase chromatography. The disclosure also relates to methods for calculating or determining the slope S of a peptide, wherein S is defined according to the Linear-Solvent-Strength equation log k=log k0?S*?. Also provided are a set of peptides with known S values suitable for use in the described methods.

Abstract: The purpose of the present invention is to provide a method to more easily analyze the concentration of glue in an electrolyte solution, while suppressing the degradation of glue during the analysis. There is provided a method for analyzing the concentration of glue contained in an electrolyte solution containing the electrolyte components by using high performance liquid chromatography, where said method comprises a step wherein an electrolyte solution is added into the eluent pH of which has been adjusted equal to or less than 5 by adding acid to an aqueous solution of phosphate of alkaline metal or alkaline earth metal, a step wherein the eluent into which the electrolyte solution has been added is passed through a separation column the exclusion limit molecular weight of which is 4000-6000 for separating the glue and electrolyte components, and a step wherein the separated glue is detected by a detector.

Abstract: The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.

Abstract: The present invention provides a method for detecting a glycan structure of a prostate specific antigen (PSA) rapidly and with high sensitivity and determining prostate carcinoma based on the difference in the structure, in particular, a method for determining between prostate carcinoma and benign prostatic hyperplasia accurately. A method for determining prostate carcinoma, wherein the method includes a step of analyzing a PSA glycan structure in a sample derived from a test subject, and prostate carcinoma is determined in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(?)).

Abstract: A first fuel and a second fuel are marked with a marker that can be detected quantitatively in a predetermined concentration range. The second fuel is marked with a binary marker. Decreased concentration of the quantitative marker, presence of a binary marker, or both may be indicative of a fuel that is altered (e.g., mixed, laundered, diluted, or adulterated). Testing a fuel includes testing the fuel for a presence of a first marker in the fuel in a predetermined concentration range, and testing the fuel for a presence of a second marker. The presence of the first marker in the predetermined concentration range and an absence of the second marker may be indicative that the fuel is unaltered. The presence of the first marker in the fuel in a concentration less than the predetermined concentration range or the presence of the second marker may be indicative that the fuel is altered.

Abstract: The present invention provides a method for determining the gender of a fetus by assaying the sex hormones, evaluating the overall reducing/oxidizing (redox) activity, and/or evaluating the radical scavenging capacity of the maternal urine or other body fluid. The method can be used to determine fetal gender at any time point during the entire pregnancy. The body fluid may be processed before assaying. Processing may involve aging the body fluid, or purification of various fractions. The methods of the present invention also provide for a means for pre-conception offspring gender planning by assaying the sex hormones, evaluating the overall reducing/oxidizing (redox) activity, and/or evaluating the radical scavenging capacity of the urine or other body fluid from a non-pregnant female. The sex hormone profiles, the overall redox activity, and/or the radical scavenging capacity of a urine sample correlates with the gender specific compatibility of the ovum being released during a particular menstrual cycle.

Abstract: The present invention provides methods for diagnosing human hepatic disorders, such as non-alcoholic steatohepatitis (NASH), identifying a human subject at risk of an adverse drug reaction, and determining an appropriate dosage of a therapeutic drug for a human subject. The marker is an increased level of acetaminophen-glucuronide in a plasma or urine sample from a human subject.

Abstract: A composition comprising synthetic peptides for use as a peptide retention standard in liquid chromatography applications is disclosed Said synthetic peptides have a broad range of hydrophobicity while maintaining low variation in their molecular weights The synthetic peptides disclosed consist of the ammo acid sequences LGGGGGGDGSR, LGGGGGGDFR, LLGGGGDFG, LLLGGDFR, LLLLDFR, LLLLLDFR A method of predicting the hydrophobicity of an unknown peptide in liquid chromatography using a composition of peptide retention standards and a method of developing a Universal Hydrophobicity Index (UHI) for the measurement of peptide hydrophobicity in liquid chromatography are also described

Abstract: The process for the diagnosis of a renal cell carcinoma comprises the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, wherein said polypeptide markers are selected from the markers as characterized in Table 1 by molecular masses and migration times.

Abstract: A method for analyzing a multi-channel chromatogram is realized for accurately resolving overlapping peaks on a multi-channel chromatogram to permit analysis of the composition of a sample. First, components of overlapping peaks are specified. A data matrix Dij is determined, and compressed in the wavelength direction to obtain a data matrix vector Di. Next, the two-dimensional data is deconvoluted, final standard deviation s0 is registered, and the deconvoluted two-dimensional data is reconvoluted to a retention intensity matrix. A quantitative spectral intensity matrix is computed, components are identified, and the identified components are quantified. Subsequently, an eigenvalue problem is solved, and the number n of components is estimated. The deconvolution and computation of the eigenvalue problem are iteratively executed until the peaks are isolated. Then, elution profiles are calculated, the components are identified, and the identified components are quantified.

Abstract: An apparatus (200) for deriving an operation mode from a first fluidic device to a second fluidic device, wherein the first fluidic device has a first target operation mode (300) representing a desired behavior of the first fluidic device and has a first real operation mode (304) representing the actual behavior of the first fluidic device, wherein the second fluidic device has a second target operation mode (312) representing a desired behavior of the second fluidic device and has a second real operation mode (314) representing the actual behavior of the second fluidic device, the apparatus (200) comprising a first determining unit (202) adapted for determining the first real operation mode (304) based on the first target operation mode (300) and based on a preknown parameterization (302) of the first fluidic device, and a second determining unit (204) adapted for determining the second target operation mode (312) based on the determined first real operation mode (304) and based on a preknown parameterizatio

Abstract: A process and to an apparatus for isotope ratio analysis having the steps of: performing an LC process and thus providing a first eluate which comprises at least one first liquid carrier fluid and one or more analytes, collecting a portion of interest from the eluate, processing the eluate portion of interest by combining with a second liquid carrier fluid and removing the first carrier fluid to form a processed eluate portion, processing the processed eluate portion to form one or more gaseous conversion products of the analytes, and supplying the gaseous conversion products with gaseous carrier fluid to an isotope analyzer and determining the isotope ratios.